Navidea Biopharmaceuticals (NAVB -1.5%) says results from a clinical trial of NAV4694 in healthy...

|About: Navidea Biopharmaceuticals (NAVB)|By:, SA News Editor

Navidea Biopharmaceuticals (NAVB -1.5%) says results from a clinical trial of NAV4694 in healthy subjects and those with diagnosed forms of dementia demonstrated imaging characteristics nearly identical to those of an acknowledged benchmark, gold-standard amyloid imaging agent, 11C-labeled Pittsburgh Compound-B. The authors believe these results show that NAV4694 may be useful in the early and differential diagnosis of Alzheimer’s disease.